145 related articles for article (PubMed ID: 24775731)
1. Emerging therapies in castration resistant prostate cancer.
Thoreson GR; Gayed BA; Chung PH; Raj GV
Can J Urol; 2014 Apr; 21(2 Supp 1):98-105. PubMed ID: 24775731
[TBL] [Abstract][Full Text] [Related]
2. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
3. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
4. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
[TBL] [Abstract][Full Text] [Related]
5. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.
Tilki D; Evans CP
Can J Urol; 2014 Apr; 21(2 Supp 1):7-13. PubMed ID: 24775718
[TBL] [Abstract][Full Text] [Related]
6. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
7. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
8. Novel agents for the management of castration-resistant prostate cancer.
Haddad H; Garcia JA
Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
[TBL] [Abstract][Full Text] [Related]
9. The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
Valdez CD; Kunju L; Daignault S; Wojno KJ; Day ML
Prostate; 2013 Dec; 73(16):1776-85. PubMed ID: 24038143
[TBL] [Abstract][Full Text] [Related]
10. Current, new and novel therapy for castration-resistant prostate cancer.
Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
[TBL] [Abstract][Full Text] [Related]
11. The future of systemic therapies for localised prostate cancer.
Eigl BJ; Gleave ME; Chi KN
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):506-13. PubMed ID: 23660300
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
13. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
14. Progress in emerging therapies for advanced prostate cancer.
Oudard S
Cancer Treat Rev; 2013 May; 39(3):275-89. PubMed ID: 23107383
[TBL] [Abstract][Full Text] [Related]
15. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
16. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
Dreicer R
Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapies targeting castration-resistant prostate cancer.
Gkialas IK; Fragkoulis C
J BUON; 2015; 20(6):1389-96. PubMed ID: 26854432
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapies in castrate-resistant prostate cancer.
Lassi K; Dawson NA
Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
[TBL] [Abstract][Full Text] [Related]
19. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
Petrylak DP
Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
[TBL] [Abstract][Full Text] [Related]
20. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
Akaza H
Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
